BPG is committed to discovery and dissemination of knowledge
Meta-Analysis
Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 21, 2026; 32(47): 123905
Published online Dec 21, 2026. doi: 10.3748/wjg.123905
Figure 5
Figure 5 Forest plots comparing hepatitis B virus DNA clearance rates between patients with chronic hepatitis B alone and those with chronic hepatitis B and metabolic dysfunction-associated fatty liver disease. A: 24 weeks; B: 48 weeks; C: 96 weeks; D: 48 weeks nucleos(t)ide analogues therapy; E: 48 weeks, interferon-based therapy. Pooled effects are expressed as odds ratios with 95%CIs. MAFLD: Metabolic dysfunction-associated fatty liver disease; CHB: Chronic hepatitis B.


Write to the Help Desk